Dow Pharma Solutions showcases pharma portfolio at CPhI NA

Dow Pharma Solutions – a division of the DowDuPont Specialty Products Division – will showcase its portfolio of pharma solutions at CPhI North America, taking place this week in Philadelphia

Dow Pharma Solutions develops functional excipients, active pharmaceutical ingredients (APIs) and medical‐grade adhesives to help patients globally.

In booth #1019 at CPhI North America, Dow Pharma Solutions will display solutions for solubility enhancement and improved release profiles to optimise drug performance, including the following:

• Ethocel High Productivity Polymers: optimised for dry powder layering processes and can coat 40‐60% faster than current multi‐particulate coating technologies
• Methocel DC2: helps shorten development time and reduces manufacturing costs by up to 60% percent in direct compression
• Affinisol HPMCAS uniquely tailored to address the solubilisation performance requirements of active pharmaceutical ingredients through stable solid dispersion and inhibition of API crystallisation. Affinisol HPMC HME provides improved thermal properties conceived for hot melt extrusion.

“With an unwavering commitment to our customers, our expansive portfolio of pharmaceutical solutions enables us to serve as a one‐stop shop to address all of our customers’ formulation needs,” said Nick Grasman, Regional Marketing Leader for Dow Pharma Solutions.

“We look forward to pushing innovation and redefining industry standards as we continue to offer the most extensive, highest‐quality pharmaceutical solutions portfolio on the market.”

Companies

• Dow Chemical Company